Quest Diagnostics (DGX) has seen a positive rally, with a 7.1% increase following its Q2 results. The announcement of new diagnostic tests and strong revenue growth have also contributed to this rise. In addition, its stock price is expected to continue growing, according to a Deutsche Bank Aktiengesellschaft analyst. Its strong Q2 results have exceeded earnings and revenue estimates. Revenue guidance for 2025 has been raised to $10.8B–$10.92B amid robust Q2 growth and an increase in advanced diagnostic momentum. Patient demand is expected to drive the company's future growth while maintaining an undervalued price today. Despite an initial slump, options traders may see something in DGX after it reported a 27.3% climb in a year based on earnings call results. A collaboration with Google Cloud aimed at improving data streamlining and personalizing customer experiences using Generative AI is also in the works. The company has announced the launch of the first-ever commercial test for the dangerous Oropouche virus and a revolutionary FDA-cleared blood test to detect early Alzheimer's with 97% accuracy.
Quest Diagnostics DGX News Analytics from Mon, 27 Jan 2025 08:00:00 GMT to Sat, 26 Jul 2025 02:51:25 GMT - Rating 8 - Innovation -3 - Rumor -4
